TriSalus Life Sciences News

Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $16

Maxim Group analyst Jason McCarthy maintains $TriSalus Life Sciences(TLSI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 29

moomoo NewsJun 4 10:32 ET

JonesTrading Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $16

JonesTrading analyst Justin Walsh maintains $TriSalus Life Sciences(TLSI.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 37.

moomoo NewsJun 4 08:31 ET

TriSalus Life Sciences Presents Liver and Pancreatic Cancer Data at ASCO 2024

TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery (PEDD) technology with immunotherapy to transform treatment for patients with liver

BenzingaJun 3 07:08 ET

Express News | TriSalus Life Sciences: Hepatic Arterial Infusion of Nelitolimod Associated With Encouraging Immunologic Activity in Patients With Hcc, ICC

ReutersJun 3 07:01 ET

Express News | TriSalus Life Sciences: Hepatic Arterial Infusion of Nelitolimod Well Tolerated

ReutersJun 3 07:01 ET

Express News | TriSalus Life Sciences Highlights Clinical Data From Phase 1B Perio-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 Asco Annual Meeting

ReutersJun 3 07:00 ET

TriSalus Life Sciences Initiated at Buy by Canaccord Genuity

TriSalus Life Sciences Initiated at Buy by Canaccord Genuity

Dow JonesMay 30 09:10 ET

Express News | Canaccord Genuity Initiates Coverage On TriSalus Life Sciences With Buy Rating, Announces Price Target of $12

BenzingaMay 30 09:00 ET

TriSalus Life Sciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 57.07% Canaccord Genuity → $12 Initiates Coverage On → Buy 05/10/2024 109.42% JonesTrading → $1

BenzingaMay 30 08:59 ET

Innovative Oncology Advancements: TriSalus Life Sciences' Market Opportunity and the TriNav Device

TipRanksMay 30 05:45 ET

LIDR, HOOK and BCAB Among Mid-day Movers

Seeking AlphaMay 24 12:58 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersInnovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) sh

BenzingaMay 24 12:31 ET

Nasdaq Gains 1%; Intuit Shares Plunge

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Friday.The Dow traded up 0.25% to 39,163.18 while the NASDAQ rose 1.04% to 16,909.33. The S&P 500 also

BenzingaMay 24 12:07 ET

Express News | TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

ReutersMay 24 06:05 ET

JonesTrading Sticks to Their Buy Rating for TriSalus Life Sciences (TLSI)

TipRanksMay 16 08:26 ET

Navigating the Financial Tightrope: Trisalus Life Sciences' High-Stakes Debt Strategy With OrbiMed

TipRanksMay 16 02:01 ET

Earnings Call Summary | TriSalus Life Sciences(TLSI.US) Q1 2024 Earnings Conference

The following is a summary of the TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript:Financial Performance:TriSalus Life Sciences reported a Q1 2024 revenue of $6.5 million, a signif

moomoo AIMay 15 12:30 ET · Conference Call

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 15 11:40 ET

10-Q: Quarterly report

SEC announcementMay 15 09:10 ET · Announcements

Express News | TriSalus Life Sciences Inc: Full Year Sales Growth Expected to Exceed 50%

ReutersMay 15 08:08 ET